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High glucocorticoid levels induced by stress enhance the memory of fearful events and may contribute to
the development of anxiety and posttraumatic stress disorder. In contrast, elevated glucocorticoids
associated with ageing impair spatial memory. We have previously shown that pharmacological inhi-
bition of the intracellular glucocorticoid-amplifying enzyme 11b-hydroxysteroid dehydrogenase type 1
(11b-HSD1) improves spatial memory in aged mice. However, it is not known whether inhibition of 11b-
HSD1 will have any beneﬁcial effects on contextual fear memories in aged mice. Here, we examined the
effects of UE2316, a selective 11b-HSD1 inhibitor which accesses the brain, on both spatial and contextual
fear memories in aged mice using a vehicle-controlled crossover study design.
Short-term UE2316 treatment improved spatial memory in aged mice, an effect which was reversed
when UE2316 was substituted with vehicle. In contrast, contextual fear memory induced by foot-shock
conditioning was signiﬁcantly reduced by UE2316 in a non-reversible manner. When the order of
treatment was reversed following extinction of the original fear memory, and a second foot-shock
conditioning was given in a novel context, UE2316 treated aged mice (previously on vehicle) now
showed increased fear memory compared to vehicle-treated aged mice (previously on UE2316). Renewal
of the original extinguished fear memory triggered by exposure to a new environmental context may
explain these effects. Thus 11b-HSD1 inhibition reverses spatial memory impairments with ageing while
reducing the strength and persistence of new contextual fear memories. Potentially this could help
prevent anxiety-related disorders in vulnerable elderly individuals.
© 2014 Elsevier Ltd. All rights reserved.1. Introduction
Prolonged exposure to elevated glucocorticoids as a conse-
quence of increased hypothalamic pituitary adrenal (HPA) axis ac-
tivity during ageing associates with impaired hippocampal synaptic
plasticity and spatial memory decline in rodents (Issa et al., 1990;
VanGuilder et al., 2011) and in humans (Dodt et al., 1994; Lupien
et al., 1998). Evidence, mainly from animal studies, suggest that
age-related spatial memory impairments result from theentre for Cardiovascular Sci-
e France Crescent, Edinburgh
) 131 242 6779.cumulative effects of elevated glucocorticoid levels on brain
structure rather than on any acute effects of high glucocorticoids
(Sapolsky, 1987; Seckl and Olsson, 1995). Indeed, rats are protected
against age-related memory impairments when circulating gluco-
corticoids are maintained at low levels throughout life such as
adrenalectomy with low dose corticosterone (CORT) replacement
or by neonatal programming (Landﬁeld et al., 1981; Meaney et al.,
1988).
Glucocorticoids readily diffuse into the brain from the circula-
tion to activate high afﬁnity mineralocorticoid receptors (MR) and
lower afﬁnity glucocorticoid receptors (GR). Both MR and GR are
expressed in limbic regions involved in cognitive function (de Kloet
et al., 1999; Oitzl and de Kloet, 1992). Tissue glucocorticoid levels
are also inﬂuenced, however, by 11b-hydroxysteroid dehydroge-
nase type 1 (11b-HSD1), an intracellular glucocorticoid-amplifying
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rodents; cortisol in humans) from circulating inert forms (11-
dehydrocorticosterone, cortisone) (Wyrwoll et al., 2011). 11b-
HSD1 is highly expressed within the hippocampus, amygdala,
cortex and other CNS regions underpinning cognition (Moisan
et al., 1990; Pelletier et al., 2007; Sandeep et al., 2004).
Glucocorticoids locally generated by 11b-HSD1 play a major role
in age-related cognitive impairments (Maclullich et al., 2010; Yau
and Seckl, 2012). Thus mice with lifelong deﬁciency of 11b-HSD1
resist age-dependent spatial memory impairments even though
plasma CORT levels are elevated to the same level as wildtype mice
(Yau et al., 2007, 2001). Conversely, transgenic mice with modest
forebrain-speciﬁc overexpression of 11b-HSD1 show accelerated
memory deﬁcits with ageing (Holmes et al., 2010). Moreover, we
have shown that just 10 days treatment with a selective 11b-HSD1
inhibitor improves spatial memory in aged mice without affecting
plasma CORT levels (Sooy et al., 2010).
Although elevated glucocorticoids or stress can impair the
retrieval of spatial memories (de Quervain et al., 1998), they also
strengthen aversive/emotional memories (Roozendaal and
McGaugh, 2011; Roozendaal et al., 2006). The hippocampus and
amygdala play dissociable roles in processing the contextual and
emotional properties of a fear memory while the prefrontal cortex
integrates the two (Phillips and LeDoux, 1992; Zelikowsky et al.,
2014). Contextual fear memory is enhanced by glucocorticoids in
a dose-dependent manner (Abercrombie et al., 2003; Okuda et al.,
2004; Roozendaal and McGaugh, 2011) and is impaired by adre-
nalectomy (Pugh et al., 1997).
Fear learning is highly adaptive and evolutionarily conserved to
protect individuals against repeated danger. But fear memories can
sometimes persist well beyond the traumatic experience. This can
predispose some individuals to anxiety-related disorders including
post-traumatic stress disorder (PTSD). One common feature of
PTSD is exaggerated and inappropriate fear responses. Moreover,
recent evidence in war veterans suggests that PTSD is associated
with a higher risk of dementia (Meziab et al., 2014).
While 11b-HSD1 inhibition is beneﬁcial in attenuating age-
related spatial memory decline, it is not known if 11b-HSD1 is
involved in glucocorticoid-associated emotional/fear memories,
notably with ageing. We therefore examined the effects of short-
term inhibition of 11b-HSD1 on spatial and contextual fear mem-
ories in aged C57BL/6J mice using a vehicle controlled cross-over
design to test whether such effects are reversible.
2. Materials and methods
2.1. Animals
Male C57BL/6J mice were bred in-house and maintained in groups of 3e5 per
cage on a 12 h light/dark cycle (lights on at 07:00 A.M.) with food and water ab
libitum until experimentation at 24 months old. All procedures and behavioural
experiments were performed between 8.00 and 11.30 a.m. and approved by the local
University of Edinburgh animal welfare ethical review body and performed in strict
accordance with the U.K. Animals (Scientiﬁc Procedures) Act, 1986.
2.2. Y-maze
Spatial memory was assessed in a two trial Y-maze task as described (Sooy et al.,
2010). The time spent in the novel armwas calculated as a percentage of total time in
all three arms. A 1 min inter-trail interval (ITI) was used to control for spontaneous
novelty exploration and to assess vision and a 2 h ITI was used to assess
hippocampal-dependent spatial recognition memory.
2.3. Contextual fear conditioning
The fear conditioning (FC) apparatus (Coulbourn Instruments, Whitehall PA)
consisted of an animal enclosure (25 cm  25 cm  38 cm) made up of two inter-
changeable aluminium side walls and Plexiglas rear and front walls with a remov-
able shock grid ﬂoor of stainless steel rods (3.2 mm diameter, 4.7 mm apart), all
housed within a sound-attenuating chamber illuminated with a single house light.
The grid ﬂoor was connected to a precision-regulated shocker that delivered theelectric footshock stimuli controlled by FreezeFrame software (Actimetrics). A
camera located on top of the FC enclosure recorded the activity of the mice. Freezing
behaviour (complete absence of movement except for breathing) was analysed us-
ing FreezeFrame software (Actimetrics). The FC enclosure was cleaned with 70%
ethanol and air-dried before each trial and between mice.
Each mouse was habituated to the FC enclosure within a neutral context (silver
aluminium tiles alongside the walls with no visual spatial cues or scents) for 4 min
on two consecutive days. On day 1 of training (after habituation), mice were placed
in the FC enclosure within an enriched context (aluminium tiles swapped for black
and white tiles placed in unique pattern with addition of vanilla or almond essence
odours) for 3 min of acclimatization. Mice were then given a context conditioned
stimulus (CS, FC enclosure context) paired with an unconditioned stimulus [US, two
electric foot shock(s) separated by a 30 s interval (2 s, 0.6 mA)]. Contextual fear
memory of the foot shock was assessed 24 h later when mice were exposed to the
same training context but without any shocks. Freezing responses were measured
for 240s in the FC enclosure. Extinction trials followed the same protocol as the
retention trials where the mice were re-exposed to the CS without reinforcement of
the US.
2.4. 11b-HSD1 activity
Hippocampal and cortex tissues were homogenised and assayed for 11-
ketosteroid reductase activity as described previously (Sooy et al., 2010).
2.5. Corticosterone radioimmunoassay (RIA)
Plasma corticosterone levels were measured using an in-house RIA (Al Dujaili
et al., 1981) modiﬁed for microtiter plate scintillation proximity assay (GE Health-
care, UK). The intra-assay and inter-assay coefﬁcients of variation were 9.4% and
9.2%, respectively.
2.6. UE2316
The novel 11b-HSD1 inhibitor (UE2316; [4-(2-chlorophenyl-4-ﬂuoro-1-
piperidinyl][5-(1H-pyrazol-4-yl)-3-thienyl]-methanone) was synthesised by High
Force Ltd, UK according to methods previously described (Webster et al., 2011).
2.7. Experimental schedule
UE2316 treatment and behavioural testing in the 24 months old C57BL/6J mice
were carried out as shown in Fig. 1. All aged C57BL/6J mice were ﬁrst tested in the Y-
maze (1 min ITI) to conﬁrm intact vision and preferential exploration of the novel
arm before random selection for either UE2316 (10 mg/kg/day) or vehicle (50%
dimethyl sulfoxide: 50% polyethylene glycol) treatment via two osmotic minipumps
(5 mg/kg/day per pump; model 2004: nominal pump rate 0.25 ml/h; Alzet, USA)
implanted subcutaneously under anaesthesia (Isoﬂurane 3%). Spatial memory was
re-assessed in the Y-maze (2 h ITI) on the 10th day of drug treatment. Four days later,
whilst still receiving drug treatment, all mice underwent contextual fear condi-
tioning as described above followed 24 h later by context retention and then three
extinction trials conducted over the course of 5 days. On the morning following the
ﬁnal extinction trial, tail venesection blood samples were taken for CORT mea-
surements. Then, on the following day, the treatment groups were crossed over such
that UE2316 pumps were replacedwith vehicle pumps and vice versa. After ten days
drug treatment, spatial memory and the retention and extinction of contextual fear
memorywere assessed as before, but with different visual spatial cues around the Y-
maze and a new context in the FC enclosure. Again, tail venesection blood samples
were taken the morning following the ﬁnal extinction trial. All mice were culled the
followingmorning by cervical dislocation and brains dissected, frozen on dry ice and
stored at 80 C for 11b-HSD1 activity assays.
2.8. Statistical analysis
Plasma CORT levels and 11b-HSD1 activity (% conversion of [3H]-11DHC to [3H]-
CORT) were analysed by Student's unpaired t-tests for between treatment group
comparisons. Y-maze data were analysed by two-way ANOVA, with treatment and
time in arms as the independent variables. Within animal comparisons of % time in
arms of Y-maze were analysed by multiple paired t-tests with Bonferroni adjusted P
value. Contextual fear memory training, retention and extinction datawere analysed
by two-way ANOVA, with footshock or days and treatment as the independent
factors. Statistical signiﬁcance was determined post-hoc by multiple t-tests using
the Holm-Sidak method, with alpha ¼ 5%. All data were analysed using GraphPad
Prism 6 software. Signiﬁcance was set at p < 0.05. Data are expressed as
means ± SEM.
3. Results
3.1. Plasma CORT levels are unaltered with 11b-HSD1 inhibition
UE2316 treatment signiﬁcantly reduced 11b-reductase activity
in the hippocampus and cortex of the aged mice measured ex vivo
Fig. 1. Experimental schedule for the effects of UE2316 treatment on spatial and contextual fear memory in a vehicle controlled cross over design. Prior to behavioural testing (Y-
maze (2 h inter-trial interval (ITI)) and fear conditioning (FC)), 24 m aged mice were treated via subcutaneously implanted Alzet osmotic minipumps with UE2316 (10 mg/kg/day) or
vehicle (n ¼ 8e9/group).
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(P < 0.001 compared to vehicle controls), Fig. 2). Plasma CORT levels
were not signiﬁcantly affected by drug treatment [initial treatment:
vehicle (33.81 ± 6.99 nM, n ¼ 8) and UE2316 (17.25 ± 5.43 nM,
n ¼ 9); cross-over treatment: vehicle (39.7 ± 8.07 nM, n ¼ 8) and
UE2316 (23.96 ± 4.48 nM, n ¼ 8)].
3.2. UE2316 reversibly improves spatial memory in aged mice
Prior to UE2316 drug treatment, all 24 m agedmice tested in the
immediate version of the Y-maze [1 min inter-trial interval (ITI)],
spent more time in the novel arm (P < 0.0001, compared to pre-
viously visited arms, Fig. 3A), conﬁrming neophilia (normal
response to the novel arm) and showing intact vision. Using the 2 h
ITI to test spatial memory retention, the resulting data showed a
signiﬁcant interaction of UE2316 treatment and % time in arms
(F2,45 ¼ 9.8, P < 0.001 and F2,45 ¼ 3.82, P < 0.05, respectively).
Vehicle control aged mice were impaired failing to spend more
time in novel arm (Fig. 3B). However, UE2316 treated aged mice
showed improved spatial memory on the 10th day of treatment
(more time in novel arm than previously visited arms (p < 0.01);
time in novel arm was greater than in vehicle controls (P < 0.01,
unpaired t-test), Fig. 3B).
To test whether the improved spatial memory persists when
UE2316 treatment stops, the osmotic minipumps were removed
and replaced with new pumps ﬁlled with UE2316 or vehicle. When
re-tested in the Y-maze (2 h ITI) on the 10th day of treatment, there
was a signiﬁcant interaction of UE2316 treatment and % time in
arms (F2,45 ¼ 8.0, P < 0.01 and F2,45 ¼ 5.69, P < 0.01, respectively).
Aged mice with treatment changed from UE2316 to vehicle,
reverted to impaired spatial memory (similar times in all three
arms; % time in novel arm was signiﬁcantly lower on vehicle than
when previously on UE2316 treatment (P < 0.05, paired t-test,
Fig. 3B and C). Conversely, aged mice with treatment changed fromFig. 2. UE2316 reduces 11b-HSD1 activity in the aged mouse brain. 11b-HSD1 activity
measured ex-vivo as % conversion of [3H]-11dehydrocorticosterone to [3H]-cortico-
sterone in hippocampus and cortex from UE2316 and vehicle treated aged mice. Re-
sults represent mean ± SEM. ***P < 0.001 vs vehicle group.vehicle to UE2316 now showed improved spatial memory (% time
in novel arm greater than previously visited arms, P < 0.01); time in
novel armwas greater than in vehicle controls (P < 0.05, unpaired t-
test, Fig. 3C) and greater than novel arm when previously on
vehicle, (P < 0.05, paired t-test, Fig. 3B and C).
3.3. UE2316 impairs contextual fear memory retention in aged mice
with effects persisting after drug withdrawal
To examine whether contextual fear memory is affected by
UE2316 treatment, aged mice were tested in the fear conditioning
apparatus following the Y-maze. During training in context A,
neither UE2316 nor vehicle treated animals displayed any freezing
prior to the footshocks but similar freezing responses were shown
immediately after the footshocks (>35%, Fig. 4A). UE2316 treated
aged mice exhibited strikingly lower levels of freezing when re-
exposed to context A for each of the 6 consecutive days after
training (F1,90 ¼ 184.5, P < 0.0001, Fig. 4B). Though both groups
given repeated re-exposure to context A over 6 days gradually
extinguished the fear memory, responses were lower in UE2316-
treated mice on each occasion (F5,90 ¼ 27.89, P < 0.0001, Fig. 4B)
and only UE2316 treated mice fully extinguished the freezing
response.
In contrast to spatial memory, the effects of UE2316 on
contextual fear memory were not reversed when drug treatments
were swapped. Aged mice previously on vehicle but now on
UE2316 exhibited low levels of freezing to the new context B
(P < 0.05, greater than vehicle controls), suggesting “renewal” of
the original fear memorywhich had not fully extinguished (Fig. 4C).
In contrast, aged mice which previously received UE2316 but now
on vehicle treatment showed minimal baseline freezing to context
B (Fig. 4C). As before, both treatment groups responded with
similar freezing responses to the footshocks. However, one day
after training, aged mice with treatment changed from UE2316 to
vehicle showed persisting reduced contextual fear memory reten-
tion (P < 0.05) compared with animals now receiving UE2316
having changed from vehicle (Fig. 4D). The levels of freezing
behaviour were gradually extinguished over subsequent days of re-
exposure to context B with no statistically signiﬁcant difference
between the groups by the second day onwards (treatment,
F1,90 ¼ 13.06, P < 0.001; days, F5,90 ¼ 6.98, P < 0.0001, Fig. 4D).
The freezing responses in aged mice on vehicle (but previously
on UE2316) were lower during the initial 3 days of re-exposure to
the new context B compared to the freezing responses of these
mice when initially on vehicle exposed to context A (F1,90 ¼ 25.08,
P < 0.0001) (Fig. 4D and B). This suggests the initial UE2316 treat-
ment effects may have persisted for some time following the swap
to vehicle and affected the new fear memory. The freezing re-
sponses of aged mice on UE2316 (but previously on vehicle) were
Fig. 3. Short-term UE2316 treatment reversibly improves spatial memory in aged
C57BL/6J mice. (A) All aged mice were tested in the immediate version of the Y-maze
(1 min inter-trial interval (ITI)) conﬁrming preferential exploration of the novel arm
and no visual problems identifying cues around the maze. (B) UE2316 improved spatial
memory (more time spent in novel arm) on the 10th day of treatment while vehicle
treated aged mice remained impaired in the Y-maze (n ¼ 8e9/group). (C) Improved
spatial memory in UE2316 treated mice reversed after swapping to vehicle, while
impaired spatial memory in vehicle-treated mice improved after swapping to UE2316.
Results represent mean ± SEM. ***P < 0.0001, xP < 0.01 and ♯P < 0.05 vs. other arms.
*P < 0.05 vs corresponding treatment.
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treated aged mice exposed to context A (F1,90 ¼ 44.62, P < 0.0001)
(Fig. 4D and B). This suggests that the initial fear memory in aged
mice on vehicle may have reactivated upon re-exposure to context
B, and not been suppressed by current UE2316 treatment.
4. Discussion
In this study we provide evidence that inhibition of 11b-HSD1
differentially modulates spatial and fear memories in aged mice,
with improvements in spatial memory, conﬁrming the results with
another 11b-HSD1 inhibitor, UE1961 (Sooy et al., 2010), but im-
pairments in contextual fear memory.
In the absence of changes in plasma CORT levels, UE2316 inhi-
bition of 11b-HSD1 to lower intracellular CORT levels in brain re-
gions important for cognition may explain the improved memory
in the aged mice. Indeed, we recently found that 10 days of UE2316
treatment reduced the dynamic rise in intrahippocampal CORT
levels during memory retrieval in a Y-maze, an effect associatedwith improved spatial memory retention (Yau et al., in press). The
rapid reversibility of the spatial memory deﬁcits on withdrawal of
UE2316 in already aged mice suggests that the impairing effects of
elevated glucocorticoids on memory are not wholly attributable to
irreversible effects on brain structure.
In contrast to spatial memory, the effects of glucocorticoids on
fear memory are more long lasting. Previous studies have shown
that glucocorticoids dose-dependently enhance the consolidation
of fear memories (Abercrombie et al., 2003; Roozendaal and
McGaugh, 2011) and that GR antagonists infused directly into the
basolateral amygdala impairs this consolidation process (Donley
et al., 2005). Thus, whereas age-related spatial memory deﬁcits
associate with elevated plasma glucocorticoids activating GRs (Yau
et al., 2011), enhanced fear/emotional memories also require GRs,
particularly in the amygdala (Kolber et al., 2008; Nikzad et al., 2011).
Indeed, chronic restraint stress, which increases plasma CORT
levels, impairs spatial memory (Luine et al., 1994) but enhances
contextual fear conditioning (Conrad et al., 1999). Furthermore,
during emotional situations when circulating glucocorticoid levels
are elevated, the hippocampus via its interactionwith the amygdala
is thought to contribute contextual information associated with the
fearful event (Richter-Levin andAkirav, 2000). A similar high level of
plasma glucocorticoids would however impair spatial memory in a
separate situation not involving a fearful event. Accordingly,
reducing local tissue CORT levels in stressedor aged animals via 11b-
HSD1 deﬁciency or inhibition would be predicted to have the
opposite effect of improving spatial memory and impairing
contextual fear memory. In support, even a single injection of
UE2316, which would transiently lower hippocampal CORT levels
has recently been shown to impair contextual fear conditioning in
young adult mice (Sarabdjitsingh et al., 2014). In the current study,
10 days of UE2316 treatment in aged mice also impaired contextual
fear memory retention. Ageing per se has not been shown to affect
the retention of contextual fear memories shortly after training
(within 10 days) (Bergado et al., 2011; Gould and Feiro, 2005; Oler
and Markus, 1998) although one study found decreased retention
of the conditioning context when tested 52 days after training in
aged rats (Oler andMarkus, 1998). Since activation of GRs located in
the hippocampus is necessary for contextual fear memory consoli-
dation (Abrari et al., 2009), lowered intrahippocampal CORT levels
associated with UE2316 treatment (Yau et al., in press), may in part
underlie the impaired contextual fear memory in the aged mice.
Furthermore, it is likely that UE2316 reduced CORT levels in other
brain regions involved in contextual fear memory (Orsini et al.,
2013; Zelikowsky et al., 2014). Although the amygdala was not
dissected formeasurement of 11b-HSD1 inhibition byUE2316 in the
present study, expression of 11b-HSD1 (Pelletier et al., 2007) and
detectable levels of UE2316 after a single peripheral dose (Cobice
et al., 2013) have been located in this brain region.
In contrast to the reversible effects of UE2316 on spatial memory
in the agedmice, the impairing effects of UE2316 on contextual fear
memory was not rapidly reversed when drug and vehicle treat-
ments were swapped following extinction of the initial fear
memory. This is not surprising since it is well established that,
although fear memories can be extinguished by repeated exposure
to the context or cue that associates with the threat, the original
fear memory is not permanently erased (Zelikowsky et al., 2012).
The process of extinction is itself a new learning that inhibits the
expression of old learning (e.g. learning to no longer fear a previ-
ously feared situation or object, usually by repeated exposure to
reminders of the original fear in a safe environment) (Quirk, 2002;
Quirk and Mueller, 2008). Aged mice on UE2316 but previously on
vehicle exhibited a signiﬁcant amount of freezing upon exposure to
a novel context consistent with “renewal” of the original extin-
guished fear (Orsini et al., 2013; Zelikowsky et al., 2012). Although
Fig. 4. Short-term UE2316 treatment impairs contextual fear memory in aged C57BL/6J mice with effects persisting after drug withdrawal. (A) When exposed to training in context
A, no freezing was observed prior to foot shocks but after each foot shock, all mice showed moderate levels of freezing which were not affected by UE2316 treatment. (B) UE2316
treatment reduced contextual fear memory retention compared to vehicle controls for each consecutive day following training. Level of freezing declined with each consecutive day
of re-exposure to context A. (C) When treatments were swapped over mice now showed low levels of freezing when exposed to training context B, even prior to the foot shocks.
UE2316 did not affect the level of freezing after each foot shock. (D) UE2316 (previously vehicle) treatment now enhanced contextual fear memory retention 1 day following
training. Level of freezing declined with each consecutive day of re-exposure to context B. Results represent mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 vs corresponding
treatment group.
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and odour), the ﬂoor grid used to deliver the shock was the same.
Thus the ﬂoor grid may itself act as a reminder that renews the
original fear memory, especially if memory of the initial context-
shock association was particularly strong or had not fully extin-
guished. Surprisingly, the impairing effect of UE2316 on contextual
fear memory appear to persist after treatment stops so that
memory of a subsequent foot-shock conditioning in new context
was less severe. How this occurs is unclear and further in-
vestigations are necessary to establish how long the effect persists.
Similar ﬁndings were observed in a human study when metyr-
apone, used to decrease glucocorticoid levels, reduced the strength
of an emotional memory trace in a long-lastingmanner with effects
still observed 4 days after drug administration (Marin et al., 2011).
Although UE2316 in aged mice appeared to cause an exag-
gerated memory response to a second round of fear conditioning
in new context, this is still likely to be less than if mice had been
exposed to two consecutive rounds of fear conditioning in
different contexts without any protection from UE2316 treat-
ment. This is because, in addition to renewal of the original fear
memory (Orsini et al., 2013; Zelikowsky et al., 2012) in vehicle-
treated aged mice, there will also be the additional retrieval of
the new fear memory during vehicle or UE2316 treatment, with
the latter being substantially impaired. Consistent with this hy-
pothesis, we have recently found that when young wildtype mice
are fear conditioned for a second time in a new context (one
week after the ﬁrst contextual fear conditioning test) there is
even greater fear memory retention, whereas 11b-HSD1 deﬁcient
mice continued to show similar reduced fear memory retention
upon exposure to each training context (Wheelan & Yau,
unpublished).In conclusion, spatial memory deﬁcits in aged mice can be
reversed by short-term UE2316 treatment but once treatment stops
the impaired memory returns. Contextual fear memories on the
other hand are impaired by UE2316 in the same aged mice but
these effects are not reversed acutely when treatment is dis-
continued because renewal of the original extinguished fear
memory in the novel context affects the new fear memory. Selec-
tive 11b-HSD1 inhibitors may not only protect against or reverse
age-related spatial memory deﬁcits but could also have the added
beneﬁt of reducing the strength of traumatic memories in vulner-
able individuals.Disclosure statement
SPW, JRS and BRW are inventors on licenced patents owned by
the University of Edinburgh covering UE2316 and related com-
pounds, and have consulted widely for companies developing 11b-
HSD1 inhibitors.Acknowledgements
Thework was supported by a PhD studentship (to NW) from the
University of Edinburgh Centre for Cognitive Ageing and Cognitive
Epidemiology, part of the cross council Lifelong Health and Well-
being Initiative (G0700704). Funding from the Biotechnology and
Biological Sciences Research Council (BBSRC), Engineering and
Physical Sciences Research Council (EPSRC), Economic and Social
Research Council (ESRC), and Medical Research Council (MRC) is
gratefully acknowledged. CJK acknowledges support from the
British Heart Foundation (through a Centre of Research Excellence
N. Wheelan et al. / Neuropharmacology 91 (2015) 71e7676Award). Development of UE2316 was supported by a Wellcome
Trust Seeding Drug Discovery award (to BRW, SPW and JRS).
References
Abercrombie, H.C., Kalin, N.H., Thurow, M.E., Rosenkranz, M.A., Davidson, R.J., 2003.
Cortisol variation in humans affects memory for emotionally laden and neutral
information. Behav. Neurosci. 117, 505e516.
Abrari, K., Rashidy-Pour, A., Semnanian, S., Fathollahi, Y., Jadid, M., 2009. Post-
training administration of corticosterone enhances consolidation of contextual
fear memory and hippocampal long-term potentiation in rats. Neurobiol. Learn.
Mem. 91, 260e265.
Al Dujaili, E.A.S., Williams, B.C., Edwards, C.R.W., 1981. The development and appli-
cation of a direct radioimmunoassay for corticosterone. Steroids 37, 157e176.
Bergado, J.A., Almaguer, W., Rojas, Y., Capdevila, V., Frey, J.U., 2011. Spatial and
emotional memory in aged rats: a behavioral-statistical analysis. Neuroscience
172, 256e269.
Cobice, D.F., Mackay, C.L., Goodwin, R.J., McBride, A., Langridge-Smith, P.R.,
Webster, S.P., Walker, B.R., Andrew, R., 2013. Mass spectrometry imaging for
dissecting steroid intracrinology within target tissues. Anal. Chem. 85,
11576e11584.
Conrad, C.D., LeDoux, J.E., Magarinos, A.M., McEwen, B.S., 1999. Repeated restraint
stress facilitates fear conditioning independently of causing hippocampal CA3
dendritic atrophy. Behav. Neurosci. 113, 902e913.
de Kloet, E.R., Oitzl, M.S., Joels, M., 1999. Stress and cognition: are corticosteroids
good or bad guys? Trends Neurosci. 22, 422e426.
de Quervain, D.J., Roozendaal, B., McGaugh, J.L., 1998. Stress and glucocorticoids
impair retrieval of long-term spatial memory. Nature 394, 787e790.
Dodt, C., Theine, K.J., Uthgenannt, D., Born, J., Fehm, H.L., 1994. Basal secretory ac-
tivity of the hypothalamo-pituitary-adrenocortical axis is enhanced in healthy
elderly. An assessment during undisturbed night-time sleep. Eur. J. Endocrinol.
131, 443e450.
Donley, M.P., Schulkin, J., Rosen, J.B., 2005. Glucocorticoid receptor antagonism in
the basolateral amygdala and ventral hippocampus interferes with long-term
memory of contextual fear. Behav. Brain Res. 164, 197e205.
Gould, T.J., Feiro, O.R., 2005. Age-related deﬁcits in the retention of memories for
cued fear conditioning are reversed by galantamine treatment. Behav. Brain Res.
165, 160e171.
Holmes, M.C., Carter, R.N., Noble, J., Chitnis, S., Dutia, A., Paterson, J.M., Mullins, J.J.,
Seckl, J.R., Yau, J.L., 2010. 11beta-hydroxysteroid dehydrogenase type 1
expression is increased in the aged mouse hippocampus and parietal cortex and
causes memory impairments. J. Neurosci. 30, 6916e6920.
Issa, A.M., Rowe, W., Gauthier, S., Meaney, M.J., 1990. Hypothalamic-pituitary-ad-
renal activity in aged, cognitively impaired and cognitively unimpaired rats.
J. Neurosci. 10, 3247e3254.
Kolber, B.J., Roberts, M.S., Howell, M.P., Wozniak, D.F., Sands, M.S., Muglia, L.J., 2008.
Central amygdala glucocorticoid receptor action promotes fear-associated CRH
activation and conditioning. Proc. Natl. Acad. Sci. U. S. A. 105, 12004e12009.
Landﬁeld, P.W., Baskin, R.K., Pitler, T.A., 1981. Brain aging correlates: retardation by
hormonal-pharmacological treatments. Science 214, 581e584.
Luine, V., Villegas, M., Martinez, C., McEwen, B.S., 1994. Repeated stress causes
reversible impairments of spatialmemory performance. Brain Res. 639,167e170.
Lupien, S.J., de Leon, M., de Santi, S., Convit, A., Tarshish, C., Nair, N.P.V., Thakur, M.,
McEwen, B.S., Hauger, R.L., Meaney, M.J., 1998. Cortisol levels during human
aging predict hippocampal atrophy and memory deﬁcits. Nat. Neurosci. 1,
69e73.
Maclullich, A.M., Ferguson, K.J., Reid, L.M., Deary, I.J., Starr, J.M., Wardlaw, J.M.,
Walker, B.R., Andrew, R., Seckl, J.R., 2010. 11beta-hydroxysteroid dehydrogenase
type 1, brain atrophy and cognitive decline. Neurobiol. Aging 33 (1), 207.e1e8.
Marin, M.F., Hupbach, A., Maheu, F.S., Nader, K., Lupien, S.J., 2011. Metyrapone
administration reduces the strength of an emotional memory trace in a long-
lasting manner. J. Clin. Endocrinol. Metab. 96, E1221eE1227.
Meaney, M.J., Aitken, D.H., van Berkel, C., Bhatnagar, S., Sapolsky, R.M., 1988. Effect
of neonatal handling on age-related impairments associated with the hippo-
campus. Science 239, 766e768.
Meziab, O., Kirby, K.A., Williams, B., Yaffe, K., Byers, A.L., Barnes, D.E., 2014. Prisoner
of war status, posttraumatic stress disorder, and dementia in older veterans.
Alzheimer's Dement. 10, S236eS241.
Moisan, M.-P., Seckl, J.R., Edwards, C.R.W., 1990. 11ß-hydroxysteroid dehydrogenase
bioactivity and messenger RNA expression in rat forebrain: localization in hy-
pothalamus, hippocampus and cortex. Endocrinology 127, 1450e1455.
Nikzad, S., Vafaei, A.A., Rashidy-Pour, A., Haghighi, S., 2011. Systemic and intra-
hippocampal administrations of the glucocorticoid receptor antagonist
RU38486 impairs fear memory reconsolidation in rats. Stress 14, 459e464.
Oitzl, M.S., de Kloet, E.R., 1992. Selective corticosteroid antagonists modulate spe-
ciﬁc aspects of spatial orientation learning. Behav. Neurosci. 106, 62e71.Okuda, S., Roozendaal, B., McGaugh, J.L., 2004. Glucocorticoid effects on object
recognition memory require training-associated emotional arousal. Proc. Natl.
Acad. Sci. U. S. A. 101, 853e858.
Oler, J.A., Markus, E.J., 1998. Age-related deﬁcits on the radial maze and in fear
conditioning: hippocampal processing and consolidation. Hippocampus 8,
402e415.
Orsini, C.A., Yan, C., Maren, S., 2013. Ensemble coding of context-dependent fear
memory in the amygdala. Front. Behav. Neurosci. 7, 199.
Pelletier, G., Luu-The, V., Li, S., Bujold, G., Labrie, F., 2007. Localization and gluco-
corticoid regulation of 11beta-hydroxysteroid dehydrogenase type 1 mRNA in
the male mouse forebrain. Neuroscience 145, 110e115.
Phillips, R.G., LeDoux, J.E., 1992. Differential contribution of amygdala and hippo-
campus to cued and contextual fear conditioning. Behav. Neurosci. 106,
274e285.
Pugh, C.R., Tremblay, D., Fleshner, M., Rudy, J.W., 1997. A selective role for cortico-
sterone in contextual-fear conditioning. Behav. Neurosci. 111, 503e511.
Quirk, G.J., 2002. Memory for extinction of conditioned fear is long-lasting and
persists following spontaneous recovery. Learn. Mem. 9, 402e407.
Quirk, G.J., Mueller, D., 2008. Neural mechanisms of extinction learning and
retrieval. Neuropsychopharmacology 33, 56e72.
Richter-Levin, G., Akirav, I., 2000. Amygdala-hippocampus dynamic interaction in
relation to memory. Mol. Neurobiol. 22, 11e20.
Roozendaal, B., McGaugh, J.L., 2011. Memory modulation. Behav. Neurosci. 125,
797e824.
Roozendaal, B., Okuda, S., Van der Zee, E.A., McGaugh, J.L., 2006. Glucocorticoid
enhancement of memory requires arousal-induced noradrenergic activation in
the basolateral amygdala. Proc. Natl. Acad. Sci. U. S. A. 103, 6741e6746.
Sandeep, T.C., Yau, J.L., MacLullich, A.M., Noble, J., Deary, I.J., Walker, B.R., Seckl, J.R.,
2004. 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive
function in healthy elderly men and type 2 diabetics. Proc. Natl. Acad. Sci. U. S.
A. 101, 6734e6739.
Sapolsky, R.M., 1987. Glucocorticoids and hippocampal damage. Trends Neurol. Sci.
10, 346e349.
Sarabdjitsingh, R.A., Zhou, M., Yau, J.L., Webster, S.P., Walker, B.R., Seckl, J.R.,
Joels, M., Krugers, H.J., 2014. Inhibiting 11beta-hydroxysteroid dehydrogenase
type 1 prevents stress effects on hippocampal synaptic plasticity and impairs
contextual fear conditioning. Neuropharmacology 81C, 231e236.
Seckl, J.R., Olsson, T., 1995. Glucocorticoids and the age-impaired hippocampus:
cause or effect? J. Endocrinol. 145, 201e211.
Sooy, K., Webster, S.P., Noble, J., Binnie, M., Walker, B.R., Seckl, J.R., Yau, J.L.W., 2010.
Partial deﬁciency or short-term inhibition of 11b-hydroxysteroid dehydroge-
nase type 1 improves cognitive function in ageing mice. J. Neurosci. 30,
13867e13872.
VanGuilder, H.D., Farley, J.A., Yan, H., Van Kirk, C.A., Mitschelen, M., Sonntag, W.E.,
Freeman, W.M., 2011. Hippocampal dysregulation of synaptic plasticity-
associated proteins with age-related cognitive decline. Neurobiol. Dis. 43,
201e212.
Webster, S.P., Seckl, J.R., Walker, B.R., Ward, P., Pallin, T.D., Dyke, H.J., Perrior, T.R.,
2011. 4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-meth-
anone Compounds and Their Use. PCT Intl WO2011/033255.
Wyrwoll, C.S., Holmes, M.C., Seckl, J.R., 2011. 11beta-hydroxysteroid dehydrogenases
and the brain: from zero to hero, a decade of progress. Front. Neuroendocrinol.
32, 265e286.
Yau, J.L., McNair, K.M., Noble, J., Brownstein, D., Hibberd, C., Morton, N., Mullins, J.J.,
Morris, R.G., Cobb, S., Seckl, J.R., 2007. Enhanced hippocampal long-term
potentiation and spatial learning in aged 11beta-hydroxysteroid dehydroge-
nase type 1 knock-out mice. J. Neurosci. 27, 10487e10496.
Yau, J.L., Noble, J., Kenyon, C.J., Hibberd, C., Kotelevtsev, Y., Mullins, J.J., Seckl, J.R.,
2001. Lack of tissue glucocorticoid reactivation in 11beta -hydroxysteroid de-
hydrogenase type 1 knockout mice ameliorates age-related learning impair-
ments. Proc. Natl. Acad. Sci. U. S. A. 98, 4716e4721.
Yau, J.L., Noble, J., Seckl, J.R., 2011. 11beta-hydroxysteroid dehydrogenase type 1
deﬁciency prevents memory deﬁcits with aging by switching from glucocorti-
coid receptor to mineralocorticoid receptor-mediated cognitive control.
J. Neurosci. 31, 4188e4193.
Yau, J.L., Seckl, J.R., 2012. Local ampliﬁcation of glucocorticoids in the aging brain
and impaired spatial memory. Front. Aging Neurosci. 4, 24.
Yau, J.L.W., Wheelan, N., Noble, J., Walker, B.R., Webster, S.P., Kenyon, C.J.,
Ludwig, M., Seckl, J.R., 2014. 11b-HSD1 ampliﬁed intrahippocampal glucocor-
ticoids and memory deﬁcits in aged mice. Neurobiol. Aging. http://dx.doi.org/
10.1016/j.neurobiolaging.2014.07.007 (in press).
Zelikowsky, M., Hersman, S., Chawla, M.K., Barnes, C.A., Fanselow, M.S., 2014.
Neuronal ensembles in amygdala, hippocampus, and prefrontal cortex track
differential components of contextual fear. J. Neurosci. 34, 8462e8466.
Zelikowsky, M., Pham, D.L., Fanselow, M.S., 2012. Temporal factors control hippo-
campal contributions to fear renewal after extinction. Hippocampus 22,
1096e1106.
